Sanford C. Bernstein restated their market perform rating on shares of Sanofi (NYSE:SNY) in a research note released on Thursday morning, The Fly reports. Sanford C. Bernstein currently has a $45.00 price objective on the stock, down from their prior price objective of $50.00.
Other equities research analysts have also recently issued reports about the stock. Barclays upgraded shares of Sanofi from an underweight rating to an equal weight rating in a report on Wednesday, November 15th. ValuEngine cut shares of Sanofi from a buy rating to a hold rating in a report on Friday, February 2nd. Cowen set a $48.00 price target on shares of Sanofi and gave the stock a hold rating in a report on Monday, December 18th. UBS Group restated a neutral rating on shares of Sanofi in a report on Monday, January 15th. Finally, JPMorgan Chase & Co. restated a neutral rating on shares of Sanofi in a report on Thursday, January 11th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has assigned a buy rating to the company’s stock. Sanofi presently has an average rating of Hold and an average target price of $49.33.
Shares of Sanofi (NYSE SNY) opened at $38.98 on Thursday. The company has a quick ratio of 1.16, a current ratio of 1.59 and a debt-to-equity ratio of 0.26. The company has a market cap of $99,599.57, a price-to-earnings ratio of 10.68, a price-to-earnings-growth ratio of 2.28 and a beta of 0.85. Sanofi has a twelve month low of $38.14 and a twelve month high of $50.65.
Several hedge funds and other institutional investors have recently modified their holdings of the company. First Republic Investment Management Inc. grew its holdings in shares of Sanofi by 1.8% during the fourth quarter. First Republic Investment Management Inc. now owns 109,651 shares of the company’s stock valued at $4,715,000 after buying an additional 1,897 shares during the last quarter. Synovus Financial Corp acquired a new position in shares of Sanofi during the fourth quarter valued at about $224,000. Valeo Financial Advisors LLC grew its holdings in shares of Sanofi by 52.7% during the fourth quarter. Valeo Financial Advisors LLC now owns 14,467 shares of the company’s stock valued at $622,000 after buying an additional 4,994 shares during the last quarter. Clifford Swan Investment Counsel LLC acquired a new position in shares of Sanofi during the fourth quarter valued at about $367,000. Finally, Afam Capital Inc. grew its holdings in shares of Sanofi by 3.5% during the fourth quarter. Afam Capital Inc. now owns 100,185 shares of the company’s stock valued at $4,308,000 after buying an additional 3,369 shares during the last quarter. Hedge funds and other institutional investors own 9.09% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Sanofi’s (SNY) “Market Perform” Rating Reiterated at Sanford C. Bernstein” was originally reported by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.com-unik.info/2018/02/11/sanofis-sny-market-perform-rating-reiterated-at-sanford-c-bernstein.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.